Award notice Supplies

Infliximab

Notice published in French. The AI analysis summarises it for you in your language.

Official notice and documents

Public buyer: Cliniques universitaires Saint Luc
Woluwe-Saint-Lambert
Place of performance: 1200 Woluwe-Saint-Lambert, Brussels-Capital
not published: buyer's address
Amount awarded: €2,492,000 excl. VAT
Planned end of contract: 24 July 2030
likely re-tender around January 2030
Bids received: 2
Form: Framework agreement
Multi-year contract: the buyer places orders as needs arise.
Procedure: Open procedure
Any company may submit a bid.
Publication: 19 August 2026
Notice language: French

AI analysis: go for it or not?

Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.

Create my free account

Unlimited analyses during the 14-day Pro trial, no card needed.

Description

Le marché concerne les fournitures de la spécialité pharmaceutique contenant le principe actif « Infliximab ».

Awarded to

Celltrion Healthcare Netherlands B.V.

CPV codes

European codes that classify what the contract is about. They are how we find the tenders for your trade.

33652000

Winning prices for comparable contracts

A quarter below: €290,000
Median: €403,000
A quarter above: €1,351,075

Amounts awarded (excl. VAT) over the last 3 years for 5 contracts in the same CPV group (3365…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.

Similar contracts already awarded

Contract	Winner	Amount
Immunoglobuline humaine normale pour administration intraveineuse Cliniques universitaires Saint Luc · 22 October 2026	CSL BEHRING	€16,277,080
Rituximab Cliniques universitaires Saint Luc · 19 August 2026	Celltrion Healthcare Netherlands B.V.	€628,800
Bévacizumab Cliniques universitaires Saint Luc · 7 July 2026	Celltrion Healthcare Netherlands B.V.	€503,440
Pomalidomide Cliniques universitaires Saint Luc · 19 May 2026	EG	€268,870
Antimycotica AZ Delta vzw · 21 October 2026	Arega Pharma NV Sandoz NV Fresenius Kabi NV Pfizer NV	€300,945

Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 573716-2026.